CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Hemodynamic Response to Nitroprusside in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Ejection Fraction Inflammation: A New Target For CAD Treatment and Prevention Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Clinical Case StudySeptember 18, 2019

JOURNAL:JAMA Cardiol. Article Link

Syncope After Percutaneous Coronary Intervention

Tsushima T, Sahadevan J, Intini A. Keywords: syncope; PCI; clinical case

ABSTRACT


A man in his late 50s with a history of remote coronary artery bypass grafting presented with unstable angina and underwent percutaneous coronary intervention with a drug-eluting stent. He was discharged and prescribed ticagrelor, 90 mg twice daily, in addition to his home regimen of aspirin and metoprolol tartrate. Three months later, he experienced worsening exertional dyspnea and had multiple episodes of syncope. He had no history of syncopal episodes or arrhythmias. His baseline transthoracic echocardiogram results demonstrated normal systolic function and no significant valvular disease. Ambulatory electrocardiogram (ECG) monitoring results showed 31 episodes of high-grade atrioventricular (AV) block (AVB), with ventricular pauses ranging from 3.0 to 13.0 seconds occurring during the day and at night. Among them, 4 episodes were associated with presyncope.